Get notified regarding key financial metrics and revenue changes at PharmericaLearn more
Banner background

Pharmerica Revenue

Pharmerica revenue was $2.09 b in FY, 2016 which is a 3.1% year over year increase from the previous period.

Embed Graph

Summary - Funding Rounds

Founding Date

2007

Investors

Pharmerica is a subsidiary of KKR

Pharmerica Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2.1b1.8b1.8b1.9b2.0b2.1b

Revenue growth, %

8%7%3%

Cost of goods sold

1.8b1.5b1.4b1.6b1.7b1.8b

Gross profit

293.3m300.2m327.2m339.3m335.1m326.0m

Gross profit Margin, %

14%16%19%18%17%16%

R&D expense

3.0m

General and administrative expense

214.9m214.7m225.3m236.3m222.5m220.6m

Operating expense total

246.3m251.4m271.4m308.9m281.3m287.6m

Depreciation and amortization

15.4m20.1m28.6m33.7m

EBIT

47.0m48.8m55.8m30.4m53.8m38.4m

EBIT margin, %

2%3%3%2%3%2%

Interest expense

8.8m10.0m10.6m9.9m6.6m9.5m

Pre tax profit

38.2m38.8m45.2m16.2m47.2m28.9m

Income tax expense

14.8m15.9m26.3m9.4m12.1m7.3m

Net Income

23.4m22.9m18.9m6.8m35.1m21.6m

Quarterly

Pharmerica Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

17.4m12.3m24.2m33.3m23.1m5.4m

Accounts Receivable

232.4m206.5m199.8m195.7m200.5m235.4m

Prepaid Expenses

34.5m38.6m38.6m90.4m52.4m

Inventories

130.5m135.7m110.3m135.7m155.2m214.7m

Current Assets

451.3m429.8m411.7m497.3m483.5m552.4m

PP&E

53.1m61.9m71.4m74.5m

Goodwill

214.2m268.2m282.6m317.7m371.0m392.3m

Total Assets

833.4m885.7m901.4m1.1b1.2b1.3b

Accounts Payable

54.1m49.2m83.8m95.5m71.7m107.1m

Short-term debt

6.3m12.5m12.5m18.0m11.6m15.6m

Current Liabilities

102.2m106.5m151.5m175.8m141.4m182.3m

Long-term debt

293.7m303.0m218.8m344.9m415.7m457.8m

Total Debt

300.0m315.5m231.3m351.3m427.3m473.4m

Common Stock

300.0k300.0k300.0k300.0k300.0k

Preferred Stock

Additional Paid-in Capital

355.9m363.0m380.2m394.1m404.6m411.1m

Retained Earnings

68.4m91.3m110.2m117.0m152.1m173.7m

Total Equity

413.8m442.6m462.5m478.1m519.4m544.2m

Debt to Equity Ratio

0.7 x0.7 x0.5 x0.7 x0.8 x0.9 x

Debt to Assets Ratio

0.4 x0.4 x0.3 x0.3 x0.4 x0.4 x

Financial Leverage

2 x2 x1.9 x2.2 x2.2 x2.4 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

14.6m10.3m6.7m12.0m49.5m7.8m12.3m52.4m12.7m11.1m7.1m25.2m21.3m40.0m25.5m27.4m6.5m15.4m13.5m7.8m

Accounts Receivable

242.8m239.9m244.3m219.3m209.9m207.7m195.3m190.5m186.2m188.1m213.7m199.5m199.1m195.8m199.5m208.1m215.4m247.8m246.6m249.2m

Prepaid Expenses

33.3m31.4m34.9m37.2m34.4m37.5m40.8m40.4m41.4m50.4m70.0m62.0m47.5m52.6m55.3m52.6m54.3m57.1m51.1m54.0m

Inventories

129.3m118.4m104.2m109.1m98.0m100.2m113.2m70.3m107.4m141.4m133.4m122.6m135.2m117.5m118.5m160.9m118.8m143.5m139.6m139.2m

Current Assets

459.9m438.8m422.9m407.3m424.9m386.4m397.0m390.5m386.4m435.9m466.1m449.7m450.2m452.3m453.4m494.2m430.0m468.8m457.4m455.3m

PP&E

51.6m54.9m57.3m59.2m62.9m65.1m70.3m70.1m70.8m71.5m74.6m76.8m84.6m87.1m88.3m89.3m

Goodwill

186.8m183.4m214.6m214.9m214.9m268.5m268.5m271.4m282.5m286.9m321.5m336.3m336.8m341.8m372.1m372.2m388.1m431.6m422.9m449.3m

Total Assets

823.4m787.6m800.4m782.3m798.2m840.9m850.3m845.1m869.4m923.4m1.0b1.0b1.1b1.1b1.2b1.2b1.2b1.3b1.2b1.3b

Accounts Payable

81.5m53.2m47.4m36.7m43.6m36.8m41.4m53.1m61.5m59.1m75.5m81.6m80.1m83.3m87.2m97.4m73.0m86.9m104.5m97.1m

Short-term debt

3.1m9.4m12.5m9.4m12.5m12.5m12.5m12.5m12.5m2.8m20.5m11.6m11.4m11.6m11.6m11.8m15.5m15.5m15.4m

Current Liabilities

125.3m102.1m92.9m90.7m101.7m93.5m104.5m108.5m113.0m125.6m132.4m154.8m155.2m167.2m149.5m168.4m138.5m161.2m177.8m176.3m

Long-term debt

274.0m257.9m262.7m237.5m234.4m259.2m244.6m221.9m218.4m358.1m317.1m338.2m326.0m366.0m400.2m378.7m451.0m417.4m444.8m

Total Debt

274.0m261.0m272.1m250.0m243.8m271.7m257.1m234.4m230.9m268.9m360.9m326.0m349.8m337.4m377.6m411.8m390.5m466.5m432.9m460.2m

Common Stock

300.0k300.0k300.0k300.0k300.0k300.0k300.0k300.0k300.0k300.0k300.0k300.0k300.0k300.0k300.0k300.0k300.0k300.0k300.0k300.0k

Preferred Stock

Additional Paid-in Capital

353.0m354.4m357.5m358.8m361.4m365.3m367.0m368.9m387.4m389.7m391.9m397.9m400.1m402.3m406.5m408.5m410.4m416.0m417.7m419.3m

Retained Earnings

55.7m60.5m74.0m81.6m87.6m101.8m112.0m105.8m115.0m105.3m113.8m126.6m128.9m131.9m156.2m158.7m166.0m177.2m181.9m185.1m

Total Equity

398.3m404.5m420.8m429.7m437.3m453.6m465.4m456.7m470.0m462.2m472.7m487.1m492.1m496.9m522.4m526.9m535.8m550.4m556.8m561.6m

Debt to Equity Ratio

0.7 x0.6 x0.6 x0.6 x0.6 x0.6 x0.6 x0.5 x0.5 x0.6 x0.8 x0.7 x0.7 x0.7 x0.7 x0.8 x0.7 x0.8 x0.8 x0.8 x

Debt to Assets Ratio

0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x0.4 x0.4 x0.4 x

Financial Leverage

2.1 x1.9 x1.9 x1.8 x1.8 x1.9 x1.8 x1.9 x1.8 x2 x2.2 x2.1 x2.1 x2.1 x2.2 x2.3 x2.2 x2.3 x2.2 x2.3 x

Pharmerica Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

23.4m22.9m18.9m6.8m35.1m21.6m

Depreciation and Amortization

20.1m18.6m40.4m51.7m57.5m

Accounts Receivable

9.1m35.8m29.1m(2.4m)(34.3m)

Inventories

(38.3m)(4.7m)(18.8m)(15.9m)(56.7m)

Accounts Payable

(25.0m)(9.3m)(2.9m)(24.0m)36.4m

Cash From Operating Activities

26.8m85.7m48.4m18.5m30.8m

Purchases of PP&E

(51.0m)(20.8m)(26.5m)(25.6m)(23.9m)(34.2m)

Capital Expenditures

(13.2m)

Cash From Investing Activities

(64.0m)(105.3m)(157.0m)(104.1m)(91.7m)

Long-term Borrowings

(240.0m)(6.3m)(231.3m)(5.5m)(11.3m)

Cash From Financing Activities

43.8m14.5m117.7m75.4m43.2m

Net Change in Cash

6.6m(5.1m)9.1m(10.2m)(17.7m)

Interest Paid

7.6m9.3m8.5m10.6m

Income Taxes Paid

500.0k12.6m19.4m(4.8m)

Free Cash Flow

13.6m

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

10.7m15.5m5.6m13.2m19.2m10.5m20.7m14.5m4.8m(4.9m)3.6m9.6m11.9m14.9m6.6m13.9m3.5m11.4m

Depreciation and Amortization

10.1m14.9m4.8m15.1m22.9m4.8m9.6m26.2m9.2m18.3m28.1m12.4m25.1m37.8m5.3m11.0m41.9m16.0m32.7m49.3m

Accounts Receivable

(8.3m)(2.2m)(12.1m)12.9m22.3m(1.2m)10.3m14.8m13.1m12.1m10.4m(2.3m)(2.2m)1.2m1.0m(7.0m)(14.4m)(5.3m)(4.1m)(6.7m)

Inventories

26.5m21.6m32.7m35.5m22.5m65.4m2.8m(31.2m)(16.3m)13.2m600.0k18.1m34.9m(7.4m)36.5m73.6m77.5m81.0m

Accounts Payable

7.0m(21.3m)(7.0m)(18.0m)(10.8m)(12.6m)(7.9m)3.8m(21.8m)(20.5m)(22.9m)(14.1m)(15.5m)(11.9m)14.2m26.8m2.3m(25.8m)(8.4m)(15.8m)

Cash From Operating Activities

300.0k12.3m19.9m51.8m103.2m47.7m74.3m152.0m4.4m(22.1m)(2.4m)44.3m22.1m59.6m62.3m41.2m80.3m72.2m114.7m132.7m

Purchases of PP&E

(8.5m)(8.5m)(6.9m)(13.5m)(6.7m)(14.0m)(20.9m)(6.0m)(12.8m)(19.0m)(4.6m)(11.0m)(17.6m)(5.4m)(13.3m)(26.3m)(7.9m)(15.9m)(23.4m)

Capital Expenditures

(6.2m)(9.4m)(2.5m)

Cash From Investing Activities

(14.7m)(17.8m)(2.4m)(7.0m)(14.0m)(7.2m)(14.4m)(25.4m)(16.3m)(29.9m)(143.3m)(25.0m)(31.5m)(38.3m)(12.1m)(20.2m)(57.5m)(56.1m)(66.6m)(117.4m)

Short-term Borrowings

3.0m

Long-term Borrowings

(240.0m)(240.0m)(100.0k)(100.0k)(6.3m)(3.1m)(6.3m)(9.4m)(3.1m)(6.3m)(231.3m)(200.0k)(500.0k)(3.3m)(2.9m)(5.8m)(8.8m)(3.9m)(7.8m)(11.7m)

Cash From Financing Activities

18.2m5.0m(28.2m)(50.2m)(57.1m)(45.0m)(59.9m)(86.5m)400.0k38.9m128.6m(27.4m)(2.6m)(14.6m)(47.8m)(16.7m)(39.4m)(6.1m)(40.0m)(12.9m)

Net Change in Cash

3.8m(500.0k)(10.7m)(5.4m)32.1m(4.5m)40.1m(11.5m)(13.1m)(17.1m)(8.1m)(12.0m)6.7m2.4m4.3m(16.6m)10.0m8.1m2.4m

Interest Paid

2.5m5.1m2.8m5.0m7.2m2.3m4.6m6.6m1.8m3.7m5.6m2.1m3.0m6.2m2.6m5.2m7.9m3.5m7.4m11.3m

Income Taxes Paid

300.0k100.0k1.3m2.2m4.0m500.0k6.4m11.9m400.0k4.7m5.7m4.7m17.0m19.4m200.0k(4.8m)(400.0k)(200.0k)200.0k

Free Cash Flow

(5.9m)2.9m17.4m

Pharmerica Ratios

USDQ2, 2011

Debt/Equity

0.7 x

Debt/Assets

0.3 x

Financial Leverage

2.1 x

Pharmerica Operating Metrics

FY, 2016

Infusion Centers

19

Pharmacies

103

Pharmerica Employee Rating

3.2496 votes
Culture & Values
3
Work/Life Balance
2.9
Senior Management
2.9
Salary & Benefits
3
Career Opportunities
2.8
Source